# Chris Boshoff

> Chris Boshoff is a post-ipo equity investor at Pfizer backing Biopharma and Biotechnology. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Pfizer](https://shizune.co/investors/profile/pfizer)
- Location: New York, United States
- Total investments: 1
- Last investment: Apr 2022
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/chris-boshoff

Chris Boshoff is a post-ipo equity investor at Pfizer in New York focused on Biopharma and Biotechnology. Chris Boshoff is the Chief Scientific Officer of Pfizer. He attended The Institute of Cancer Research.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 100% |
| Biotechnology | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Zentalis Pharmaceuticals | Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical business dedicated to finding and developing small molecule medicines that target cancer's underlying biological pathways. It employs an integrated discovery engine to find targets and produce small molecule new chemical entities, or NCEs, with features that it believes couldresult in potentially distinct product profiles. Its pipeline includes two lead product candidates: ZN-c5, which is being developed for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer, and ZN-c3, which is being developed for the treatment of advanced solid tumors as monotherapy and ovarian cancer. | $25M | Post-IPO Equity | Apr 27, 2022 |  |

1 of 1 investments shown.

## About Pfizer

VC Fund · New York, United States

Pfizer provides access to safe and effective and affordable medicines and health care services. They have a portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that havethe potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.

5 contacts available at Pfizer.

| Name | Title | Profile |
| --- | --- | --- |
| Alessandra Leone | Global CMC Sr. Manager | https://shizune.co/investors/profile/alessandra-leone |
| Angela L Coral | Senior Manager, Partnerships & Impact Reporting, Global Health & Social Impact | https://shizune.co/investors/profile/angela-l-coral |
| Barbara Dalton | Senior Managing Partner, Pfizer Ventures; VP, Worldwide Business Development | https://shizune.co/investors/profile/barbara-dalton |
| Chris Boshoff | CSO | https://shizune.co/investors/profile/chris-boshoff |
| Chris O’Donnell | Partner, Pfizer Ventures & Executive Director, Emerging Sciences & Innovation | https://shizune.co/investors/profile/chris-o-donnell |

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Chris Boshoff invest in?

Chris Boshoff invests primarily in Biopharma, Biotechnology and Pharmaceutical startups, most often at Post-IPO Equity stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chris Boshoff last invest?

The most recent investment recorded for Chris Boshoff closed in Apr 2022. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co